Showing results (501-510 of 1,835) with videos related to

Sort By:
Pageof 184
ESMO Open|October 4, 2021
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year updateM Reck, T-E Ciuleanu, M Cobo, et al.
ESMO Open|July 11, 2022
A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202)S Rao, G Anandappa, J Capdevila, et al.
ESMO Open|July 17, 2022
Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancerK Hotta, T Hida, H Nokihara, et al.
ESMO Open|April 23, 2022
Predictive preoperative clinical score for patients with liver-only oligometastatic colorectal cancerG Filippini Velázquez, S Schiele, M Gerken, et al.
ESMO Open|July 6, 2019
Expanding the TNM for cancers of the colon and rectum using machine learning: a demonstrationMatthew Hueman, Huan Wang, Donald Henson, et al.
ESMO Open|July 6, 2019
New emerging targets in cancer immunotherapy: the role of Cluster of Differentiation 40 (CD40/TNFR5)Manuel Piechutta, Anna Sophie Berghoff
ESMO Open|February 19, 2022
Correlation between treatment effects on response rate and progression-free survival and overall survival in trials of targeted therapies in molecularly enriched populationsB J Solomon, H H Loong, Y Summers, et al.
ESMO Open|February 18, 2022
ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group's perspectiveT Koessler, M Alsina, D Arnold, et al.
ESMO Open|February 14, 2022
Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II studyS Park, J-M Sun, Y-L Choi, et al.
ESMO Open|March 13, 2022
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIANL Paz-Ares, Y Chen, N Reinmuth, et al.
Pageof 184